Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
HYPERION THERAPEUTICS INC (HPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/26/2015 8-K Quarterly results
11/06/2014 8-K Quarterly results
08/07/2014 8-K Quarterly results
05/06/2014 8-K Quarterly results
02/27/2014 8-K Quarterly results
11/12/2013 8-K Form 8-K - Current report
02/25/2013 8-K Quarterly results
Docs: "Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results South San Francisco, CA - February 25, 2013 - Hyperion Therapeutics, Inc. today reported financial operating results for the fourth quarter and the year ended December 31, 2012. According to Chief Executive Officer, Donald J. Santel, “Since the FDA's approval of RAVICTI™ on February 1st, we have been singularly focused on our commercial roll-out and expect to have product available for launch by the end of April. Specifically, we have begun the training of our sales and market access field teams and have initiated reimbursement dialogues with key private and public payers. We also expect to begin the final due diligence review related to our option to purchase BUPHENYL ® Tablets and Powder and AMMONUL ® inj..."
09/06/2012 8-K Quarterly results
Docs: "Hyperion Therapeutics Announces Second Quarter 2012 Operating Results South San Francisco, CA - September 6, 2012 - Hyperion Therapeutics, Inc. today reported consolidated financial results for the second quarter of 2012. The company reported cash and cash equivalents of $7.3 million as of June 30, 2012. Subsequent to the end of the quarter, on July 31, 2012, the company successfully closed its initial public offering and the underwriters exercised their over-allotment option in full raising proceeds, net of underwriter discounts, of $53.5 million. The company intends to use the proceeds primarily for the potential launch of its first drug, Ravicti ™ . According to Chief Executive Officer, Donald J. Santel, “Having a completed IPO makes us well positioned for the potential approval and lau..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy